ITI Pharma and Healthcare Fund Direct - Growth
(Scheme Rating)
NAV as of Sep 05, 2025
17.53-0.11%
- Growth - Direct
(Earn upto 1.88% Extra Returns with Direct Plan)
Fund Category:
Equity: Sectoral-Pharma
Expense Ratio:
0.47%(0.69% Category
average)Fund Size:
Rs. 235.68 Cr(0.70% of Investment in Category)
- ADD TO PORTFOLIO
Loading...
ADD TO PORTFOLIO
ITI Pharma and Healthcare Fund Direct - Growth
(Scheme Rating)
NAV as of Sep 05, 2025
17.53-0.11%
Expense Ratio:
0.47%
Fund Size:
Rs. 235.68 Cr
Fund Category:
Equity: Sectoral-Pharma
ITI Pharma and Healthcare Fund Direct - Growth Fund Key Highlights
1. Current NAV: The Current Net Asset Value of the ITI Pharma and Healthcare Fund - Direct Plan as of Sep 05, 2025 is Rs 17.53 for Growth option of its Direct plan.
2. Returns: Its trailing returns over different time periods are: -1.77% (1yr), 23.52% (3yr) and 15.8% (since launch). Whereas, Category returns for the same time duration are: 0.08% (1yr), 23.44% (3yr) and 18.74% (5yr).
3. Fund Size: The ITI Pharma and Healthcare Fund - Direct Plan currently holds Assets under Management worth of Rs 235.68 crore as on Jul 31, 2025.
4. Expense ratio: The expense ratio of the fund is 0.47% for Direct plan as on Sep 04, 2025.
5. Exit Load: ITI Pharma and Healthcare Fund - Direct Plan shall attract an Exit Load, "Exit load of 0.50%, if redeemed within 3 months."
6. Minimum Investment: Minimum investment required is Rs 5000 and minimum additional investment is Rs 1000. Minimum SIP investment is Rs 500.
1. Current NAV: The Current Net Asset Value of the ITI Pharma and Healthcare Fund - Direct Plan as of Sep 05, 2025 is Rs 17.53 for Growth option of its Direct plan.
2. Returns: Its trailing returns over different time periods are: -1.77% (1yr), 23.52% (3yr) and 15.8% (since launch). Whereas, Category returns for the same time duration are: 0.08% (1yr), 23.44% (3yr) and 18.74% (5yr).
3. Fund Size: The ITI Pharma and Healthcare Fund - Direct Plan currently holds Assets under Management worth of Rs 235.68 crore as on Jul 31, 2025.
4. Expense ratio: The expense ratio of the fund is 0.47% for Direct plan as on Sep 04, 2025.
5. Exit Load: ITI Pharma and Healthcare Fund - Direct Plan shall attract an Exit Load, "Exit load of 0.50%, if redeemed within 3 months."
6. Minimum Investment: Minimum investment required is Rs 5000 and minimum additional investment is Rs 1000. Minimum SIP investment is Rs 500.
ITI Pharma and Healthcare Fund Direct - Growth Returns
Trailing Returns
Rolling Returns
Discrete Period
SIP Returns
1M 3M 6M 1Y 3Y 5Y Annualized Returns -0.56 1.40 9.85 -1.77 23.52 - Category Avg 0.10 3.29 11.80 -0.07 23.24 18.74 Rank within Category 20 19 18 15 8 - No. of funds within Category 29 27 27 23 16 9 - Loading...
- Loading...
Return Comparison
- This Fund
- BenchmarkNIFTY Healthcare Total Return Index.
Choose from Benchmarks
- S&P BSE Sensex
- Nifty 50
- 1M
- 3M
- 6M
- 1Y
- 5Y
Loading...
ITI Pharma and Healthcare Fund Direct - Growth Fund Details
Investment Objective - The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare.
| Fund House | ITI Mutual Fund |
| Launch Date | Nov 08, 2021 |
| Benchmark | NIFTY Healthcare Total Return Index. |
| Return Since Launch | 15.8% |
| Riskometer | Very High |
| Type | Open-ended |
| Risk Grade | Average |
| Return Grade | Average |
ITI Pharma and Healthcare Fund Direct - Growth Investment Details
| Minimum Investment (Rs.) | 5,000.00 |
| Minimum Additional Investment (Rs.) | 1,000.00 |
| Minimum SIP Investment (Rs.) | 500.00 |
| Minimum Withdrawal (Rs.) | 1,000.00 |
| Exit Load Exit load of 0.50%, if redeemed within 3 months. | |
Portfolio Allocation
Asset Allocation
Loading...
Asset Allocation History
Loading...
EquityDebtCash
Sector Allocation
Loading...
Market Cap Allocation
Loading...
Concentration & Valuation Analysis
| JUL 2025 | JUN 2025 | MAY 2025 | APR 2025 | MAR 2025 | FEB 2025 | |
|---|---|---|---|---|---|---|
| Number of Holdings | 45 | 39 | 39 | 39 | 39 | 39 |
| Top 5 Company Holdings | 36.05% | 37.62% | 40.31% | 39.43% | 38.51% | 38.87% |
| Top 10 Company Holdings | 54.45% | 56.05% | 59.18% | 58.97% | 57.23% | 58.05% |
| Company with Highest Exposure | Sun Pharmaceutical Industries (10.93%) | Sun Pharmaceutical Industries (11.99%) | Sun Pharmaceutical Industries (15.18%) | Sun Pharmaceutical Industries (16.72%) | Sun Pharmaceutical Industries (16.22%) | Sun Pharmaceutical Industries (15.86%) |
| Number of Sectors | 6 | 4 | 4 | 3 | 3 | 3 |
| Top 3 Sector Holdings | 96.17% | 96.25% | 98.77% | 97.5% | 97.95% | 97.88% |
| Top 5 Sector Holdings | 97.98% | 97.26% | 99.7% | 97.5% | 97.95% | 97.88% |
| Sector with Highest Exposure | Healthcare (89.82%) | Healthcare (90.75%) | Healthcare (93.84%) | Healthcare (93.28%) | Healthcare (93.58%) | Healthcare (93.61%) |
Top Stock Holdings
Sector Holdings in MF
Company Sector Assest(%) P/E EPS-TTM(₹) RETURN 1 YR(%) Sun Pharmaceutical Industries Healthcare 10.93 36.57 43.23 -12.66 Divi's Laboratories Healthcare 8.68 69.39 86.87 16.96 Max Healthcare Institute Healthcare 6.12 97.39 11.80 30.21 Apollo Hospitals Enterprise Healthcare 5.66 71.15 109.43 13.00 Suven Pharmaceuticals Healthcare 4.66 151.39 6.69 -23.10 Torrent Pharmaceuticals Healthcare 4.58 61.08 59.15 4.75 Aurobindo Pharma Healthcare 3.66 17.81 58.39 -32.09 Fortis Healthcare Healthcare 3.51 81.96 11.50 73.34 Lupin Healthcare 3.46 24.04 81.00 -13.85 Aster DM Healthcare Healthcare 3.19 104.04 6.14 55.10
Peer Comparison
Cumulative Returns
SIP returns
Discrete Returns
Quant Measures
Asset Allocation
Scheme Name NAV(Rs./Unit) Scheme Rating AUM(Rs. Cr) 1M 1Y 3Y 5Y ITI Pharma and Healthcare Fund Direct - Growth 17.53 235.68 2.29 -1.35 23.16 - SBI Healthcare Opportunities Fund Direct Plan-Growth 496.05 4,026.55 -0.03 5.68 27.99 22.26 UTI Healthcare Fund Direct-Growth 330.96 1,146.13 2.25 3.77 26.35 20.58 ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth 43.10 6,103.96 2.43 4.40 28.72 22.80 DSP Healthcare Fund Direct - Growth 43.49 3,190.15 0.38 -0.94 26.27 20.47
Risk Ratios
Ratios are calculated using the calendar month returns for the last 3 years
Standard Deviation
Standard Deviation
Standard deviation is the deviation of the fund's return around mean.
High Volatality
15.60VS15.14Fund Vs Category Avg
Beta
Beta
Beta shows the portfolio risk in relation to the market. A beta of less than 1 means that the fund returns are less volatile compared to the broader market. A beta of more than 1 means that the fund returns are more volatile than the broader markets. A beta equal to 1 means that fund's volatility is in line with the broader market.
High Volatality
0.95VS0.91Fund Vs Category Avg
Sharpe Ratio
Sharpe Ratio
Sharpe ratio is a risk adjusted performance measure. A fund with a higher Sharpe ratio is considered better than a fund with a lower Sharpe ratio.
Poor risk-adjusted returns
0.99VS1.10Fund Vs Category Avg
Treynor's Ratio
Treynor's Ratio
Treynor is a risk adjusted performance measure. A fund with a higher Treynor ratio is considered better than a fund with a lower Treynor ratio.
Poor risk-adjusted returns
16.35VS18.34Fund Vs Category Avg
Jensen's Alpha
Jensen's Alpha
Alpha shows the ability of the fund manager to outperform the market. A higher Alpha is preferred.
Poor risk-adjusted returns
-0.66VS1.12Fund Vs Category Avg
Mean Return
Mean Return
Average return generated by the fund during a specified period.
Poor average monthly returns
21.83VS22.93Fund Vs Category Avg
Risk Ratio Chart
Loading...
- Risk Ratio
- Category Average
Size of Bubbles represents the Fund Size
ITI Mutual Fund News
- ITI Mutual Fund launches new brand identity ‘Diviniti Specialized Investment Fund’
- Know Your Fund Manager | Rohan Korde, Fund Manager - Equity, ITI Mutual Fund
- NFO Insight: ITI gets lucky with timing of consumption fund. Is this the best time to invest?
- NFO Alert: ITI Mutual Fund launches Bharat Consumption Fund
Fund Manager
- R.K.Rohan KordeSince Oct 202112 schemes
- D.S.Dhimant ShahSince Dec 20228 schemes
Mr. Korde is a Masters in Management Studies (Finance), Bachelor of Commerce Prior to joining ITI Mutual Fund, he has worked with BOB Capital Markets as Vice President
Scheme Name Category Nav(Rs./Unit) Scheme Rating Asset(Rs. Cr) 1Y ITI Large Cap Fund Direct - Growth Large Cap 19.00 522.55 -4.19 ITI Mid Cap Fund Direct - Growth Mid Cap 22.60 1,223.89 -7.19 ITI Multi Cap Fund Direct - Growth Multi Cap 26.29 1,275.41 -5.16 ITI Small Cap Fund Direct-Growth Small Cap 31.31 2,679.81 -2.00 ITI Value Fund Direct - Growth Value Oriented 17.58 330.62 -8.22 ITI Balanced Advantage Fund Direct - Growth Dynamic Asset Allocation 16.12 401.55 2.90 ITI Banking and Financial Services Fund Direct - Growth Sectoral-Banking 15.73 310.07 6.85 ITI Arbitrage Fund Direct - Growth Arbitrage 13.69 48.92 7.37 ITI Bharat Consumption Fund Direct-Growth Thematic-Consumption 11.79 Unrated 246.90 - ITI Large & Mid Cap Fund Direct-Growth Large & MidCap 9.65 Unrated 862.42 - ITI Focused Fund Direct - Growth Flexi Cap 15.50 Unrated 533.70 0.23 ITI Flexi Cap Fund Direct - Growth Flexi Cap 18.40 Unrated 1,193.76 -2.77 Mr. Shah is a B.Com (H) and Chartered Accountant. Prior to joining ITI Mutual Fund, he has worked with Principal Mutual Fund, HSBC AMC, Reliance Mutual Fund, ASK Raymond James Securities Pvt. Ltd. and IL&FS AMC. Senior Analyst from April 1997 to August 2003.
Scheme Name Category Nav(Rs./Unit) Scheme Rating Asset(Rs. Cr) 1Y ITI ELSS Tax Saver Fund Direct - Growth ELSS 26.82 420.01 -3.49 ITI Mid Cap Fund Direct - Growth Mid Cap 22.60 1,223.89 -7.19 ITI Value Fund Direct - Growth Value Oriented 17.58 330.62 -8.22 ITI Multi Cap Fund Direct - Growth Multi Cap 26.29 1,275.41 -5.16 ITI Small Cap Fund Direct-Growth Small Cap 31.31 2,679.81 -2.00 ITI Bharat Consumption Fund Direct-Growth Thematic-Consumption 11.79 Unrated 246.90 - ITI Focused Fund Direct - Growth Flexi Cap 15.50 Unrated 533.70 0.23 ITI Flexi Cap Fund Direct - Growth Flexi Cap 18.40 Unrated 1,193.76 -2.77
More ITI Mutual Fund
| Scheme Name | Rating | Asset Size(Cr) | 1M | 3M | 6M | 1Y | 3Y |
|---|---|---|---|---|---|---|---|
| ITI Small Cap Fund Direct-Growth | 2,679.81 | -0.88 | -0.50 | 18.76 | -2.00 | 27.39 | |
| ITI Multi Cap Fund Direct - Growth | 1,275.41 | 0.18 | -0.43 | 17.55 | -5.16 | 20.74 | |
| ITI Mid Cap Fund Direct - Growth | 1,223.89 | -0.88 | -1.74 | 14.47 | -7.19 | 22.91 | |
| ITI Flexi Cap Fund Direct - Growth | 1,193.76 | -0.14 | 0.44 | 17.09 | -2.77 | - | |
| ITI Large & Mid Cap Fund Direct-Growth | 862.42 | 0.25 | -2.32 | 12.67 | - | - | |
| ITI Focused Fund Direct - Growth | 533.70 | -1.07 | 0.32 | 15.88 | 0.23 | - | |
| ITI Large Cap Fund Direct - Growth | 522.55 | 0.06 | -1.08 | 10.70 | -4.19 | 15.32 | |
| ITI ELSS Tax Saver Fund Direct - Growth | 420.01 | 0.24 | -1.50 | 15.63 | -3.49 | 21.71 | |
| ITI Balanced Advantage Fund Direct - Growth | 401.55 | 1.04 | 1.00 | 8.18 | 2.90 | 13.34 | |
| ITI Value Fund Direct - Growth | 330.62 | -0.85 | -1.12 | 12.84 | -8.22 | 19.80 |
Mutual Fund Tools
Top AMCs
- SBI Mutual Fund
- ICICI Prudential Mutual Fund
- HDFC Mutual Fund
- Nippon India Mutual Fund
- Kotak Mahindra Mutual Fund
- Aditya Birla Sun Life Mutual Fund
- UTI Mutual Fund
- Axis Mutual Fund
- Mirae Asset Mutual Fund
- DSP Mutual Fund
- Tata Mutual Fund
- Bandhan Mutual Fund
- Edelweiss Mutual Fund
- HSBC Mutual Fund
- Invesco Mutual Fund
About ITI Pharma and Healthcare Fund Direct - Growth
1. ITI Pharma and Healthcare Fund - Direct Plan is Open-ended Sectoral-Pharma Equity scheme which belongs to ITI Mutual Fund House.
2. The fund was launched on Nov 08, 2021.
Investment objective & Benchmark
1. The investment objective of the fund is that " The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. "
2. It is benchmarked against NIFTY Healthcare Total Return Index..
Asset Allocation & Portfolio Composition
1. The asset allocation of the fund comprises around 98.71% in equities, 0.0% in debts and 1.29% in cash & cash equivalents.
2. While the top 10 equity holdings constitute around 54.45% of the assets, the top 3 sectors constitute around 96.17% of the assets.
3. The fund largely follows a Growth oriented style of investing and invests across market capitalisations - around 0.0% in giant & large cap companies, 0.0% in mid cap and 0.0% in small cap companies.
Tax Implications on ITI Pharma and Healthcare Fund Direct - Growth
1. Gains are taxed at a rate of 15% (Short-term Capital Gain Tax - STCG) if units are redeemed within 1 year of investment.
2. For units redeemed after 1 year of investment, gains of upto Rs. 1 lakh accruing from those units in a financial year shall be exempted from tax.
3. Gains of more than Rs. 1 lakh will be taxed at a rate of 10% (Long-term Capital Gain Tax - LTCG).
4. For Dividend Distribution Tax, the dividend income from this fund will get added to the income of an investor and taxed according to his/her respective tax slabs.
5. Also, for dividend income in excess of Rs 5,000 in a financial year; the fund house shall deduct a TDS of 10% on such income.
1. ITI Pharma and Healthcare Fund - Direct Plan is Open-ended Sectoral-Pharma Equity scheme which belongs to ITI Mutual Fund House.
2. The fund was launched on Nov 08, 2021.
Investment objective & Benchmark
1. The investment objective of the fund is that " The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. "
2. It is benchmarked against NIFTY Healthcare Total Return Index..
Asset Allocation & Portfolio Composition
1. The asset allocation of the fund comprises around 98.71% in equities, 0.0% in debts and 1.29% in cash & cash equivalents.
2. While the top 10 equity holdings constitute around 54.45% of the assets, the top 3 sectors constitute around 96.17% of the assets.
3. The fund largely follows a Growth oriented style of investing and invests across market capitalisations - around 0.0% in giant & large cap companies, 0.0% in mid cap and 0.0% in small cap companies.
Tax Implications on ITI Pharma and Healthcare Fund Direct - Growth
1. Gains are taxed at a rate of 15% (Short-term Capital Gain Tax - STCG) if units are redeemed within 1 year of investment.
2. For units redeemed after 1 year of investment, gains of upto Rs. 1 lakh accruing from those units in a financial year shall be exempted from tax.
3. Gains of more than Rs. 1 lakh will be taxed at a rate of 10% (Long-term Capital Gain Tax - LTCG).
4. For Dividend Distribution Tax, the dividend income from this fund will get added to the income of an investor and taxed according to his/her respective tax slabs.
5. Also, for dividend income in excess of Rs 5,000 in a financial year; the fund house shall deduct a TDS of 10% on such income.
This Might Catch Your Interest
FAQs about ITI Pharma and Healthcare Fund Direct - Growth
- Is it safe to invest in ITI Pharma and Healthcare Fund - Direct Plan?As per SEBI’s latest guidelines to calculate risk grades, investment in the ITI Pharma and Healthcare Fund - Direct Plan comes under Very High risk category.
- What is the category of ITI Pharma and Healthcare Fund - Direct Plan?ITI Pharma and Healthcare Fund - Direct Plan belongs to the Equity : Sectoral-Pharma category of funds.
- How Long should I Invest in ITI Pharma and Healthcare Fund - Direct Plan?The suggested investment horizon of investing into ITI Pharma and Healthcare Fund - Direct Plan is >3 years. The suggested investment horizon is the minimum time required for holding investments in the fund to reduce its downside risk and ensure that the returns become more predictable.
- Who manages the ITI Pharma and Healthcare Fund - Direct Plan?The ITI Pharma and Healthcare Fund - Direct Plan is managed by Rohan Korde (Since Oct 18, 2021) and Dhimant Shah (Since Dec 01, 2022).
Date Sources: Mutual Funds, ETFs, and NPS data are sourced from Value Research. All times stamps are reflecting IST (Indian Standard Time). By using this site, you agree to the Terms of Service and Privacy Policy.
